The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Two Cases of Refractory Adult-Onset Still's Disease Responding to Anakinra

치료 불응성 성인형 스틸병: 아나킨라 사용 후 임상 호전을 보인 증례 보고

  • Oh, Ji-Min (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Hyung-Jin (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jae-Joon (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn, Joong-Kyong (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, You-Sun (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Koh, Eun-Mi (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cha, Hoon-Suk (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 오지민 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 김형진 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 이재준 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 안중경 (성균관대학교 의과대학 강북삼성병원 내과) ;
  • 이유선 (성균관대학교 의과대학 삼성창원병원 내과) ;
  • 고은미 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 차훈석 (성균관대학교 의과대학 삼성서울병원 내과)
  • Published : 2012.04.01
⟨ Previous Next ⟩

Abstract

Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder with variable clinical features. The interleukin (IL)-1 receptor antagonist anakinra has been proposed as an alternative effective treatment in refractory AOSD. We report, for the first time in Korea, two cases of refractory AOSD in which anakinra treatment produced a clinical response. The first patient had frequent clinical flare-ups with fever, sore throat, myalgia, and pleuritic chest pain despite treatment with methotrexate and etanercept. In the second patient, treatments with various immunosuppressive agents failed to control the disease activity. Treatment with anakinra 100 mg/day was initiated in both cases. A complete clinical remission and improvement in the laboratory parameters were observed. The steroid dose was tapered without further clinical flare-ups. Anakinra appears to be an effective alternative treatment modality in patients with AOSD refractory to conventional disease-modifying anti-rheumatic drugs and corticosteroid therapy.

성인형 스틸병은 전신적 염증 질환으로 기존의 치료에 반응하지 않는 경우가 드물지 않다. 인터루킨-1 길항제인 anakinra는 불응성 성인형 스틸병의 대체 치료로 제시되고 있다. 저자들은 아나킨라 치료로 임상 호전을 보인 두 명의 불응성 성인형 스틸병 환자를 경험하였기에 한국에서 처음으로 이를 보고하는 바이다.

Keywords

References

  1. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008;17:349-359. https://doi.org/10.1517/13543784.17.3.349
  2. Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 2004;63:1300-1306. https://doi.org/10.1136/ard.2003.013680
  3. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-1803. https://doi.org/10.1002/art.21061
  4. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991;70:118-136. https://doi.org/10.1097/00005792-199103000-00004
  5. Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003;30:2422-2427.
  6. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-1486. https://doi.org/10.1084/jem.20050473
  7. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006;65:564-572. https://doi.org/10.1136/ard.2005.042143
  8. Aikawa NE, Ribeiro AC, Saad CG, et al. Is anti-TNF switching in refractory Still's disease safe and effective? Clin Rheumatol 2011;30:1129-1134. https://doi.org/10.1007/s10067-011-1735-0
  9. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388-3389. https://doi.org/10.1002/art.10620
  10. Lanza F, Dominici M, Govoni M, et al. Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:1307-1310. https://doi.org/10.1038/sj.bmt.1702435
  11. Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still's disease. Rheumayol Int 2011 Jan 29 [Epub]. http://dx.doi.org/10.1007/S00296-011-1801-6.
  12. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007;66:842-843. https://doi.org/10.1136/ard.2006.066381
  13. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-308.
  14. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118-1125. https://doi.org/10.3899/jrheum.090074
  15. Maier J, Birkenfeld G, Pfirstinger J, Schölmerich J, Fleck M, Bruhl H. Effective treatment of steroid refractory adult‐onset Still's disease with anakinra. J Rheumatol 2008;35:939-941.

Cited by

  1. A Case of Adult Onset Still's Disease with Severe Pneumonitis Treated with Anakinra vol.87, pp.2, 2012, https://doi.org/10.3904/kjm.2014.87.2.245